Lion Biotechnologies Inc
Lion Biotechnologies Inc operates in various business sectors.
Lion Biotechnologies Inc (2LB) - Total Liabilities
Latest total liabilities as of June 2024: €195.78 Million EUR
Based on the latest financial reports, Lion Biotechnologies Inc (2LB) has total liabilities worth €195.78 Million EUR as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lion Biotechnologies Inc - Total Liabilities Trend (2018–2023)
This chart illustrates how Lion Biotechnologies Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lion Biotechnologies Inc Competitors by Total Liabilities
The table below lists competitors of Lion Biotechnologies Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BONTERRA ENERGY (QNC1.SG)
STU:QNC1
|
Germany | €439.91 Million |
|
RED ROBIN GRMT BURG
BE:RRN
|
Germany | €722.78 Million |
|
Equals Group PLC
LSE:EQLS
|
UK | GBX35.46 Million |
|
IMPREGILO
BE:IPJ1
|
Germany | €14.47 Billion |
|
Beeio Honey Ltd
TA:BHNY
|
Israel | ILA964.00K |
Liability Composition Analysis (2018–2023)
This chart breaks down Lion Biotechnologies Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lion Biotechnologies Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lion Biotechnologies Inc (2018–2023)
The table below shows the annual total liabilities of Lion Biotechnologies Inc from 2018 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €195.74 Million | +19.10% |
| 2022-12-31 | €164.34 Million | +5.57% |
| 2021-12-31 | €155.67 Million | +39.04% |
| 2020-12-31 | €111.96 Million | +145.07% |
| 2019-12-31 | €45.68 Million | +212.31% |
| 2018-12-31 | €14.63 Million | -- |